|

intratumoral injection of autologous CD1c (BDCA-1)+ myDC Clinical Trials

1 actively recruiting trial

Also known as: intratumoral injection of ipilimumab and avelumab, intravenous nivolumab

Other1 trial

Intratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.